Put companies on watchlist
Evonik Industries AG
ISIN: DE000EVNK013
WKN: EVNK01
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Evonik Industries AG · ISIN: DE000EVNK013 · EQS - adhoc news (6 News)
Country: Germany · Primary market: Germany · EQS NID: 1881517
16 April 2024 10:30AM

Evonik publishes preliminary figures for the first quarter of 2024


EQS-Ad-hoc: Evonik Industries AG / Key word(s): Preliminary Results/Quarter Results
Evonik Industries AG: Evonik publishes preliminary figures for the first quarter of 2024

16-Apr-2024 / 10:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Evonik publishes preliminary figures for the first quarter of 2024

Essen, April 16, 2024. Evonik Industries AG publishes the following preliminary key financial figures for the first quarter of 2024 already today.

Based on preliminary figures, Evonik achieved an adjusted EBITDA* of just under €522 million in the first quarter of 2024 (Q1 2023: €409 million), thus well above market expectations (analyst consensus disclosed by Vara Research on March 26, 2024: around €450 million).  The Specialty Additives and Nutrition & Care divisions recorded the strongest growth. The upturn was driven by higher sales volumes: Following seven quarters of declines, volumes were above the previous year's level. In addition to a slight upturn in end customer demand, restocking in light of low inventory levels at customers also contributed to the higher volumes.

According to preliminary figures, Evonik’s sales amounted to €3.796 billion in the first quarter of 2024, compared with €4.0 billion in the prior-year quarter. This was mainly due to declining sales prices as a result of lower raw material costs. Consensus expected this number to be approximately €3.883 billion.

Evonik continues to expect adjusted EBITDA* of between €1.7 billion and €2.0 billion and sales of between €15 billion and €17 billion.

Evonik Industries AG will publish final figures and the quarterly report for the first quarter 2024 as planned on May 8, 2024.

*Notes on key performance indicators (KPIs) can be found in the Financial Report 2023 of Evonik Industries AG starting on page 240.

The Financial Report 2023 is available at:
https://files.evonik.com/shared-files/evonik-financial-report-2023-9492.pdf             


 

Contact/person making the notification:
Tim Lange
Head of Investor Relations
+49 201 177-3150
tim.lange@evonik.com



End of Inside Information

16-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: investor-relations@evonik.com
Internet: www.evonik.com
ISIN: DE000EVNK013
WKN: EVNK01
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1881517

 
End of Announcement EQS News Service

1881517  16-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1881517&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Evonik Industries AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.